CURIS INC (CRIS)

Nasdaq Biotechnology Diagnostics SIC: 2836
D
Pipeline Grade

Financial Position (from SEC Filings)

$15.5M
Cash & Equivalents
$9.0M
Quarterly Burn Rate
5 mo
Est. Cash Runway
$21M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT07107750 Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or ... PHASE1 Recruiting 48

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for CRIS.

SEC EDGAR Filings

All SEC filings for CURIS INC on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.